Over the past decade, we have witnessed a revolution in sequencing technologies that has had a profound impact on our understanding of genetics and genome biology. The next generation sequencing technology (NGS) has thus provided a great
potential in the management and treatment of human health bridging to a new era of molecular pathology and personalized medicine. Eastern Biotech & Life Sciences proudly adds to its portfolio several NEW Cancer Genetic tests that will use the
Next Generation Sequencing (NGS) technology. The cutting-edge technology utilizes a multi-target approach to detect mutation in specific genes & be able to detect various cancers.
BRCA1/2 Full Sequencing with Deletion & Duplication
BRCA1 and BRCA2 are tumor suppressor genes that have an essential role in both DNA repair and cell cycle control systems. Germline BRCA1 and BRCA2 mutations are implicated in 25-50% of hereditary breast cancer cases. The genetic test analyzes the BRCA1 and BRCA2 genes to identify any inherited changes (mutations) in them that can increase the risk for cancer.
BreastNext™ is a next generation sequencing (NGS) panel that simultaneously analyzes 17 genes associated with increased risk for breast cancer, including BRCA1 and BRCA2. Mutations in the genes on the BreastNext panel can confer an estimated 20–87% lifetime risk for breast cancer. Some of these genes have also been associated with increased risks for other cancers, such as pancreatic cancer, ovarian cancer, and sarcoma
BRCAplus™ is a next generation sequencing panel of 6 genes associated with breast cancer (BRCA1, BRCA2, CDH1, PALB2, PTEN, and TP53). These six genes are associated with five hereditary cancer syndromes (hereditary breast and ovarian cancer or HBOC, hereditary diffuse gastric cancer, hereditary breast and pancreatic cancer, Cowden syndrome, and Li-Fraumeni syndrome).
ColoNext is a next generation sequencing (NGS) panel that simultaneously analyzes 17 genes associated with increased risk for colorectal cancer. Full gene sequencing is performed for 15 of the genes. Gross deletion/duplication analysis is performed for all 17 genes. Specific site Analysis is available for individual gene mutations identified in a family.
Comprehensive Cancer Panel
Comprehensive Cancer Panel is a next generation full gene sequencing hereditary cancer panel that simultaneously analyzes 122 genes associated with the most common hereditary cancers such as Breast, Ovarian, Colorectal, Endometrial, Melanoma, Pancreatic, Gastric, Prostrate, Thyroid, and many more. About 10% of all cancer cases are due to hereditary cancer. The identification of the genetic cause of cancer in these patients allows the development of a personalized plan for clinical management for the affected patient and family members.